 Neoplasm Proteins
"Neoplasm Proteins" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm.
| Descriptor ID |
D009363
|
| MeSH Number(s) |
D12.776.624
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Neoplasm Proteins".
Below are MeSH descriptors whose meaning is more specific than "Neoplasm Proteins".
This graph shows the total number of publications written about "Neoplasm Proteins" by people in this website by year, and whether "Neoplasm Proteins" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1991 | 1 | 0 | 1 | | 1992 | 1 | 0 | 1 | | 1993 | 0 | 1 | 1 | | 1994 | 2 | 2 | 4 | | 1995 | 1 | 3 | 4 | | 1996 | 6 | 3 | 9 | | 1997 | 2 | 0 | 2 | | 1998 | 5 | 4 | 9 | | 1999 | 4 | 1 | 5 | | 2000 | 7 | 5 | 12 | | 2001 | 5 | 4 | 9 | | 2002 | 3 | 9 | 12 | | 2003 | 6 | 6 | 12 | | 2004 | 10 | 5 | 15 | | 2005 | 7 | 6 | 13 | | 2006 | 14 | 4 | 18 | | 2007 | 8 | 8 | 16 | | 2008 | 8 | 8 | 16 | | 2009 | 10 | 6 | 16 | | 2010 | 8 | 0 | 8 | | 2011 | 3 | 3 | 6 | | 2012 | 5 | 9 | 14 | | 2013 | 9 | 8 | 17 | | 2014 | 6 | 5 | 11 | | 2015 | 9 | 3 | 12 | | 2016 | 8 | 4 | 12 | | 2017 | 11 | 3 | 14 | | 2018 | 11 | 5 | 16 | | 2019 | 8 | 2 | 10 | | 2020 | 4 | 6 | 10 | | 2021 | 5 | 0 | 5 |
To return to the timeline, click here.
Below are the most recent publications written about "Neoplasm Proteins" by people in Profiles.
-
Daver N, Salhotra A, Brandwein JM, Podoltsev NA, Pollyea DA, Jurcic JG, Assouline S, Yee K, Li M, Pourmohamad T, Samineni D, Sumiyoshi T, Vaze A, Dere RC, Ma C, Cooper J. A Phase I dose-escalation study of DCLL9718S, an antibody-drug conjugate targeting C-type lectin-like molecule-1 (CLL-1) in patients with acute myeloid leukemia. Am J Hematol. 2021 05 01; 96(5):E175-E179.
-
Younis RH, Ghita I, Elnaggar M, Chaisuparat R, Theofilou VI, Dyalram D, Ord RA, Davila E, Tallon LJ, Papadimitriou JC, Webb TJ, Bentzen SM, Lubek JE. Soluble Sema4D in Plasma of Head and Neck Squamous Cell Carcinoma Patients Is Associated With Underlying Non-Inflamed Tumor Profile. Front Immunol. 2021; 12:596646.
-
Tengesdal IW, Menon DR, Osborne DG, Neff CP, Powers NE, Gamboni F, Mauro AG, D'Alessandro A, Stefanoni D, Henen MA, Mills TS, De Graaf DM, Azam T, Vogeli B, Palmer BE, Pietras EM, DeGregori J, Tan AC, Joosten LAB, Fujita M, Dinarello CA, Marchetti C. Targeting tumor-derived NLRP3 reduces melanoma progression by limiting MDSCs expansion. Proc Natl Acad Sci U S A. 2021 03 09; 118(10).
-
Mathew D, Torres RM. Lysophosphatidic Acid Is an Inflammatory Lipid Exploited by Cancers for Immune Evasion via Mechanisms Similar and Distinct From CTLA-4 and PD-1. Front Immunol. 2020; 11:531910.
-
Sopfe J, Greffe B, Treece AL. Metastatic NUT Midline Carcinoma Treated With Aggressive Neoadjuvant Chemotherapy, Radiation, and Resection: A Case Report and Review of the Literature. J Pediatr Hematol Oncol. 2021 01; 43(1):e73-e75.
-
Youmans DT, Gooding AR, Dowell RD, Cech TR. Competition between PRC2.1 and 2.2 subcomplexes regulates PRC2 chromatin occupancy in human stem cells. Mol Cell. 2021 02 04; 81(3):488-501.e9.
-
Frederick BA, Gupta R, Atilano-Roque A, Su TT, Raben D. Combined EGFR1 and PARP1 Inhibition Enhances the Effect of Radiation in Head and Neck Squamous Cell Carcinoma Models. Radiat Res. 2020 11 10; 194(5):519-531.
-
Kim KB, Kim Y, Rivard CJ, Kim DW, Park KS. FGFR1 Is Critical for RBL2 Loss-Driven Tumor Development and Requires PLCG1 Activation for Continued Growth of Small Cell Lung Cancer. Cancer Res. 2020 11 15; 80(22):5051-5062.
-
Laskowski J, Renner B, Pickering MC, Serkova NJ, Smith-Jones PM, Clambey ET, Nemenoff RA, Thurman JM. Complement factor H-deficient mice develop spontaneous hepatic tumors. J Clin Invest. 2020 08 03; 130(8):4039-4054.
-
Lindholm KE, Ewalt MD. Hemophagocytic syndrome-associated intravascular large B-cell lymphoma. Blood. 2020 06 25; 135(26):2432.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|